CNS Drugs

, Volume 21, Issue 8, pp 677–692 | Cite as

Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson’s Disease

Review Article

Abstract

Parkinson’s disease is a neurodegenerative disorder that affects approximately 1% of people over the age of 60 years. Levodopa is standard, and often initial, therapy for patients with this condition; however, with continued treatment and as the disease progresses, up to 80% of patients experience ‘wearing-off’ symptoms, dyskinesias and other motor complications. These levodopa-associated problems may become disabling and profoundly affect quality of life. Medications commonly used to manage these symptoms include monoamine oxidase type B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, the NMDA receptor antagonist amantadine and dopamine receptor agonists.

Agents that block MAO-B, such as rasagiline and selegiline, are used as both initial and adjunctive therapy in patients with Parkinson’s disease. These medications increase concentrations of dopamine in the brain by blocking its reuptake from the synaptic cleft, a mechanism that can slow motor decline, increase ‘on’ time and improve symptoms of Parkinson’s disease. Adverse events with these agents can include confusion, hallucination and orthostatic hypotension. MAO-B inhibition may elicit drug-drug interactions if administered with TCAs, SSRIs or serotonin-noradrenaline (norepinephrine) reuptake inhibitors. Conventional oral selegiline is associated with potentially harmful plasma concentrations of three major amfetamine metabolites, although metabolite concentrations are significantly lower with a new orally disintegrating tablet (ODT) selegeline formulation. Selegiline ODT is also absorbed more efficiently and shows less pharmacokinetic variability than conventional oral selegiline.

COMT mediates peripheral catabolism of levodopa. Therefore, agents that block COMT, such as tolcapone and entacapone, increase the elimination half-life of levodopa. Given adjunctively with levodopa, COMT inhibitors can decrease ‘off’ time and increase ‘on’ time, as well as lower the daily levodopa dose. Although more potent than entacapone, tolcapone requires monitoring for hepatotoxicity.

Amantadine is a noncompetitive NMDA receptor antagonist shown to lower dyskinesia scores and improve motor complications in patients with Parkinson’s disease when given adjunctively with levodopa.

Dopamine agonists, also used as initial and adjunctive therapy in Parkinson’s disease, improve motor response and decrease ‘off’ time purportedly through direct stimulation of dopamine receptors. Current dopamine agonists include bromocriptine, pergolide, cabergoline, lisuride, apomorphine, pramipexole, ropinirole and rotigotine. Although effective, this class of medications can be associated with cardiovascular and psychiatric adverse effects that can limit their utility.

All medications used to manage levodopa-associated motor complications in patients with Parkinson’s disease have had differing degrees of success. Although head-to-head comparisons of drugs within classes are rare, some differences have emerged related to effects on motor fluctuations, dyskinesias and on/off times, as well as to adverse effects. When choosing a drug to treat levodopa-induced complications, it is important to consider the risks and benefits of the different classes and of the specific agents within each class, given the different efficacy and safety profiles of each.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this review. Dr Jankovic has acted as a consultant for Allergan, Eisai, Merz and Teva, and has received grants from Allergan, Amersham, Boehringer-Ingelheim, Cergene, Medtronic, Merz, Prestwick, Teva and Schwarz Pharma. Dr Stacy has acted as a consultant for and/or received honoraria and grants from GlaxoSmithKline, Novartis, Boehringer-Ingelheim, Vernalis, EMD Biosciences, Schantz and Schwarz Pharma.

References

  1. 1.
    Samii A, Nutt JG, Ransom BR. Parkinson’s disease. Lancet 2004; 363(9423): 1783–93PubMedCrossRefGoogle Scholar
  2. 2.
    Hampton T. Parkinson disease registry launched. JAMA 2005; 293(2): 149PubMedCrossRefGoogle Scholar
  3. 3.
    de Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. Lancet Neurol 2006; 5(6): 525–35PubMedCrossRefGoogle Scholar
  4. 4.
    Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med 2003; 348(14): 1356–64PubMedCrossRefGoogle Scholar
  5. 5.
    Jankovic J. Pathophysiology and assessment of parkinsonian symptoms and signs. In: Pahwa R, Lyons KE, Koller WC, editors. Handbook of Parkinson’s disease. 4th ed. New York: Taylor & Francis Group, LLC, 2007: 49–75Google Scholar
  6. 6.
    Chaudhuri KR, Healy DG, Shapira AH, et al. Non-motor symp- toms of Parkinson’s disease: diagnosis and management. Lancet Neurol 2006; 5: 235–45PubMedCrossRefGoogle Scholar
  7. 7.
    Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov Disord 2004; 19(9): 997–1005PubMedCrossRefGoogle Scholar
  8. 8.
    Dewey Jr RB. Management of motor complications in Parkinson’s disease. Neurology 2004; 62Suppl. 4: S3–7PubMedCrossRefGoogle Scholar
  9. 9.
    Jankovic J. Levodopa strengths and weaknesses. Neurology 2002; 58Suppl. 1: S19–32PubMedCrossRefGoogle Scholar
  10. 10.
    Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord 2005; 20Suppl, 11: S11–6PubMedCrossRefGoogle Scholar
  11. 11.
    Marjama-Lyons JM, Koller WC. Parkinson’s disease: update in diagnosis and symptom management. Geriatrics 2001; 56(8): 24–30, 33PubMedGoogle Scholar
  12. 12.
    Obeso JA, Grandas F, Vaamonde J, et al. Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology 1989; 39Suppl. 2: 11–9PubMedGoogle Scholar
  13. 13.
    Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson’s disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005; 20(6): 726–33PubMedCrossRefGoogle Scholar
  14. 14.
    Stacy M, Hauser R, Oertel W, et al. End of dose wearing-off in Parkinson’s disease: a 9-question survey assessment. Clin Neuropharmacol 2006; 29(6): 312–32PubMedCrossRefGoogle Scholar
  15. 15.
    Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov Disord 2005; 20(2): 224–30PubMedCrossRefGoogle Scholar
  16. 16.
    Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365(9463): 947–54PubMedCrossRefGoogle Scholar
  17. 17.
    Jankovic J. An update on the treatment of Parkinson’s disease [Melvin D. Yahr memorial lecture]. Mt Sinai J Med 2006; 73(4): 682–9PubMedGoogle Scholar
  18. 18.
    Olanow CW, Jankovic J. Neuroprotective therapy in Parkinson’s disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord 2005; 20Suppl. 11: S3–10PubMedCrossRefGoogle Scholar
  19. 19.
    Kurth MC. Using liquid levodopa in the treatment of Parkinson’s disease: a practical guide. Drugs Aging 1997; 10(5): 332–40PubMedCrossRefGoogle Scholar
  20. 20.
    Stocchi F, Vacca L, Ruggieri S, et al. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005; 62(6): 905–10PubMedCrossRefGoogle Scholar
  21. 21.
    Nilsson D, Hansson LE, Johansson K, et al. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson’s disease. Acta Neurol Scand 1998; 97(3): 175–83PubMedCrossRefGoogle Scholar
  22. 22.
    Rao SS, Hofmann LA, Shakil A. Parkinson’s disease: diagnosis and treatment. Am Fam Physician 2006; 74(12): 2046–54PubMedGoogle Scholar
  23. 23.
    Allain H, Destée A, Petit H, et al. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson’s disease. Eur Neurol 2000; 44(1): 22–30PubMedCrossRefGoogle Scholar
  24. 24.
    Churchyard A, Mathias CJ, Boonkongchuen P, et al. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997; 63(2): 228–34PubMedCrossRefGoogle Scholar
  25. 25.
    Waters CH, Sethi KD, Hauser RA, et al. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004; 19(4): 426–32PubMedCrossRefGoogle Scholar
  26. 26.
    Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis and management of Parkinson’s disease. CMAJ 2003; 168(3): 293–301PubMedGoogle Scholar
  27. 27.
    Churchyard A, Mathias CJ, Lees AJ. Selegiline-induced postural hypotension in Parkinson’s disease: a longitudinal study on the effects of drug withdrawal. Mov Disord 1999; 14(2): 246–51PubMedCrossRefGoogle Scholar
  28. 28.
    Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62(2): 241–8CrossRefGoogle Scholar
  29. 29.
    Radad K, Gille G, Rausch W-D. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson’s disease. Pharmacol Rep 2005; 57(6): 701–12PubMedGoogle Scholar
  30. 30.
    Goetz CG, Poewe W, Rascol O, et al. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease, 2001 to 2004. Mov Disord 2005; 20(5): 523–39PubMedCrossRefGoogle Scholar
  31. 31.
    Henchcliffe C, Schumacher HC, Burgut FT. Recent advances in Parkinson’s disease therapy: use of monoamine oxidase inhibitors. Expert Rev Neurother 2005; 5(6): 811–21PubMedCrossRefGoogle Scholar
  32. 32.
    Dostinex [package insert]. New York; Pfizer Inc, 2004Google Scholar
  33. 33.
    Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 2006; 355(9): 896–908PubMedCrossRefGoogle Scholar
  34. 34.
    Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section: Pt I. Early (uncomplicated) Parkinson’s disease. Eur J Neurol 2006; 13(11): 1170–85Google Scholar
  35. 35.
    Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007; 68(4): 272–6PubMedCrossRefGoogle Scholar
  36. 36.
    Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline: an update. Clin Pharmacokinet 1997; 33(2): 91–102PubMedCrossRefGoogle Scholar
  37. 37.
    Mercuri NB, Scarponi M, Bonci A, et al. Monoamine oxidase inhibition causes a long-term prolongation of the dopamine-induced responses in rat midbrain dopaminergic cells. J Neurosci 1997; 17(7): 2267–72PubMedGoogle Scholar
  38. 38.
    Goetz CG, Schwid SR, Eberly SW, et al. Safety of rasagiline in elderly patients with Parkinson disease. Neurology 2006; 66(9): 1427–9PubMedCrossRefGoogle Scholar
  39. 39.
    Azilect [package insert]. Kfar Saba; Teva Pharmaceutical Industries Ltd, 2006Google Scholar
  40. 40.
    Clarke CE. Rasagiline for motor complications in Parkinson’s disease. Lancet 2005; 365(9463): 914–6PubMedCrossRefGoogle Scholar
  41. 41.
    Demarcaida JA, Schwid SR, White WB, et al. Effects of tyramine administration in Parkinson’s disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord 2006; 21(10): 1716–21PubMedCrossRefGoogle Scholar
  42. 42.
    Shin H-S. Metabolism of selegiline in humans: identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos 1997; 25(6): 657–62PubMedGoogle Scholar
  43. 43.
    Cedarbaum JM, Toy LH, Green-Parsons A. L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson’s disease patients with motor response fluctuations. Clin Neuropharmacol 1991; 14(3): 228–34PubMedCrossRefGoogle Scholar
  44. 44.
    Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism Trial. Ann Neurol 2002; 51(5): 604–12PubMedCrossRefGoogle Scholar
  45. 45.
    Pålhagen S, Heinonen E, Hägglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006; 66: 1200–6PubMedCrossRefGoogle Scholar
  46. 46.
    The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1993; 328(3): 176–83CrossRefGoogle Scholar
  47. 47.
    Clarke A, Jankovic J. Selegiline orally disintegrating tablet in the treatment of Parkinson’s disease. Therapy 2006; 3(3): 349–56Google Scholar
  48. 48.
    Lew MF. Selegiline orally disintegrating tablets for the treatment of Parkinson’s disease. Expert Rev Neurother 2005; 5(6): 705–12PubMedCrossRefGoogle Scholar
  49. 49.
    Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet 2002; 41(9): 661–80PubMedCrossRefGoogle Scholar
  50. 50.
    Fuh J-L, Lee R-C, Wang S-J, et al. Swallowing difficulty in Parkinson’s disease. Clin Neurol Neurosurg 1997; 99(2): 106–12PubMedGoogle Scholar
  51. 51.
    Zelapar (selegiline hydrochloride) orally disintegrating tablets [package insert]. Costa Mesa (CA); Valeant Pharmaceuticals International, 2006Google Scholar
  52. 52.
    Clarke A, Brewer F, Johnson ES, et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 2003; 110(11): 1241–55PubMedCrossRefGoogle Scholar
  53. 53.
    Heikkinen H, Nutt JG, LeWitt PA, et al. The effects of different repeated doses of entacapone on the pharmacokinetics of L-dopa and on the clinical response to L-dopa in Parkinson’s disease. Clin Neuropharmacol 2001; 24(3): 150–7PubMedCrossRefGoogle Scholar
  54. 54.
    Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson’s disease: an update. Clin Pharmacokinet 2006; 45(2): 109–36PubMedCrossRefGoogle Scholar
  55. 55.
    Widnell KL, Cornelia C. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. Mov Disord 2005; 20Suppl. 11: S30–7PubMedCrossRefGoogle Scholar
  56. 56.
    Olanow CW. Tolcapone and hepatotoxic effects. Arch Neurol 2000; 57(2): 263–7PubMedCrossRefGoogle Scholar
  57. 57.
    Lew M, Kricorian G. Results from a 2-year centralized tolcapone liver enzyme monitoring program [abstract no. 1035]. J Neurol Sci 2005; 238Suppl. 1: S363Google Scholar
  58. 58.
    Factor SA, Molho ES, Feustel PJ, et al. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson’s disease. Clin Neuropharmacol 2001; 24(5): 295–9PubMedCrossRefGoogle Scholar
  59. 59.
    Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson’s disease. Mov Disord 2007; 22 (1): 14-9Google Scholar
  60. 60.
    Luginger E, Wenning GK, Bosch S, et al. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease. Mov Disord 2000; 15(5): 873–8PubMedCrossRefGoogle Scholar
  61. 61.
    Snow BJ, Macdonald L, Mcauley D, et al. The effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000; 23(2): 82–5PubMedCrossRefGoogle Scholar
  62. 62.
    Verhagen Metman L, Del Dotto P, Blanchet PJ, et al. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Amino Acids 1998; 14(1–3): 75–82Google Scholar
  63. 63.
    Verhagen Metman L, Del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology 1998; 50(5): 1323–6PubMedCrossRefGoogle Scholar
  64. 64.
    Bonuccelli U. Comparing dopamine agonists in Parkinson’s disease. Curr Opin Neurol 2003; 16Suppl. 1: S13–9PubMedCrossRefGoogle Scholar
  65. 65.
    Bonnet AM, Serre I, Marconi R, et al. A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine. Mov Disord 1995; 10(5): 668–71PubMedCrossRefGoogle Scholar
  66. 66.
    Tintner R, Manian P, Gauthier P, et al. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson disease. Arch Neurol 2005; 62(8): 1290–5PubMedCrossRefGoogle Scholar
  67. 67.
    Hayashi R, Tako K, Mikashita H, et al. Efficacy of low-dose lisuride infusion in Parkinson’s disease. Intern Med 1998; 37(5): 444–8PubMedCrossRefGoogle Scholar
  68. 68.
    Woitalla D, Müller T, Benz S, et al. Transdermal lisuride delivery in the treatment of Parkinson’s disease. J Neural Transm Suppl 2004; 68: 89–95PubMedCrossRefGoogle Scholar
  69. 69.
    Guttman M, the International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. Neurology 1997; 49(4): 1060–5PubMedCrossRefGoogle Scholar
  70. 70.
    Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997; 49(1): 162–8PubMedCrossRefGoogle Scholar
  71. 71.
    Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole Study Group. Neurology 1998; 51(4): 1057–62Google Scholar
  72. 72.
    Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342(20): 1484–91PubMedCrossRefGoogle Scholar
  73. 73.
    Whone AL, Watts RL, Stoessl AJ, et al. Slower progression in early Parkinson’s disease treated with ropinirole compared with 1-dopa: the REAL-PET study. Ann Neurol 2003; 54(1): 93–101PubMedCrossRefGoogle Scholar
  74. 74.
    Jankovic J, Watts RL, Martin W, et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson’s disease. Arch Neurol 2007; 64: 676–82PubMedCrossRefGoogle Scholar
  75. 75.
    Kenney C, Jankovic J. Rotigotine transdermal patch in the treatment of Parkinson’s disease and restless legs syndrome. Expert Opin Pharmacother 2007; 8(9): 1329–35PubMedCrossRefGoogle Scholar
  76. 76.
    Kolls B, Stacy M. Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease. Clin Neuropharmacol 2006; 29(5): 292–301PubMedCrossRefGoogle Scholar
  77. 77.
    Dewey Jr RB, Hutton JT, LeWitt PA, et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001; 58(9): 1385–92PubMedCrossRefGoogle Scholar
  78. 78.
    Factor SA. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson’s disease. Neurology 2004; 62(6 Suppl. 4): S12–7PubMedCrossRefGoogle Scholar
  79. 79.
    Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356(1): 29–38PubMedCrossRefGoogle Scholar
  80. 80.
    Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 2007; 356(1): 39–46PubMedCrossRefGoogle Scholar
  81. 81.
    Lu C, Bharmal A, Suchowersky O. Gambling and Parkinson disease [letter]. Arch Neurol 2006; 63(2): 298PubMedCrossRefGoogle Scholar
  82. 82.
    Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006; 21(4): 524–9PubMedCrossRefGoogle Scholar
  83. 83.
    Stocchi F. Pathological gambling in Parkinson’s disease. Lancet Neurol 2005; 4(10): 590–2PubMedCrossRefGoogle Scholar
  84. 84.
    Prescrire editorial staff. Hypersexuality due to dopaminergic drugs. Prescrire Int 2005; 14(80): 224Google Scholar
  85. 85.
    Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology 2003; 61(3): 422–3PubMedCrossRefGoogle Scholar
  86. 86.
    Homann CN, Wenzel K, Suppan K, et al. Sleep attacks in patients taking dopamine agonists: review. BMJ 2002; 324(7352): 1483–7PubMedCrossRefGoogle Scholar
  87. 87.
    Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson’s disease: a meta-analysis. Drug Saf 2003; 26(6): 439–44PubMedCrossRefGoogle Scholar
  88. 88.
    Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. The Parkinson Study Group. N Engl J Med 1999; 340 (10): 757-63Google Scholar
  89. 89.
    Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004; 62(3): 381–8PubMedCrossRefGoogle Scholar
  90. 90.
    Diamond A, Jankovic J. Treatment of advanced Parkinson’s disease. Expert Rev Neurother 2006; 6(8): 1181–97PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Parkinson’s Disease Center and Movement Disorders Clinic, Department of NeurologyBaylor College of MedicineHoustonUSA
  2. 2.Division of Neurology, Movement Disorders CenterDuke University Medical CenterDurhamUSA

Personalised recommendations